Long term follow up and comparative study of fecal microbiota after vonoprazan and low-dose amoxicillin dual therapy or vonoprazan-based triple therapy for Helicobacter pylori infection

Long term follow up and comparative study of fecal microbiota after vonoprazan and low-dose amoxicillin dual therapy or vonoprazan-based triple therapy for Helicobacter pylori infection - Long term follow up of fecal microbiota after vonoprazan dual or triple therapies for H. pylori infection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040025

Enrollment

Registered

2020-04-01

Start date

2020-04-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

vonoprazan 20 mg twice/day and amoxicillin 750 mg twice/day for 7 days. vonoprazan 20 mg twice/day, amoxicillin 750 mg twice/day, and clarithromycin 200 mg twice/day for 7 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients who have participated the previous randomized controlled trial of vonoprazan-based dual or triple therapies for first line H. pylori eradication (UMIN000034140) and submitted fecal samples before the treatments. 2. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Lack of informed consent

Design outcomes

Primary

Measure	Time frame
The changes of fecal microbiota between baselines and 1 year after the treatments.	—

Countries

Japan

Contacts

Public ContactSho Suzuki

Nihon University School of Medicine Division of Gastroenterology and Hepatology, Department of Medicine

s.sho.salubriter.mail@gmail.com03-3293-1711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026